CDK1 and lung carcinoma: Previous studies have demonstrated that decreased phospho-Cdk1 (Thr161) expression (30), as well as the accumulation of phospho-Cdk1 (Tyr15) (31), are involved in G2/M arrest and apoptosis in lung cancer, thus validating Cdk1 as a possible therapeutic target.